PMID- 30604703
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220331
IS  - 0970-2113 (Print)
IS  - 0974-598X (Electronic)
IS  - 0970-2113 (Linking)
VI  - 36
IP  - 1
DP  - 2019 Jan-Feb
TI  - Adverse effects observed in lung cancer patients undergoing first-line 
      chemotherapy and effectiveness of supportive care drugs in a resource-limited 
      setting.
PG  - 32-37
LID - 10.4103/lungindia.lungindia_321_17 [doi]
AB  - BACKGROUND: Lung cancer (LC) chemotherapy results in several adverse events 
      (AEs). Data regarding supportive care medications (SCMs) offered to prevent/treat 
      AEs in resource-limited settings are lacking. A prospective observational study 
      was carried out to find the effectiveness of SCMs in real-life setting. METHODS: 
      Newly diagnosed LC patients receiving first-line chemotherapy at a tertiary 
      referral center in North India (from July 2014 to September 2015) were enrolled. 
      Incidence, timing of onset, duration, and grades of chemotherapy-related AEs were 
      recorded. We assessed compliance to mandatory SCMs using a structured 
      questionnaire. Patients also recorded various symptoms, frequency of need-based 
      SCMs, visits to local practitioners, and hospitalization (if any) during the 
      intercycle period. RESULTS: Of the 112 patients enrolled, majority were males 
      (83.9%, n = 94), current/ex-smokers (82.1%, n = 92), had advanced stage (Stage 
      IIIB = 33.9% [n = 38] and Stage IV = 46.4% [n = 52]), and were non-small cell 
      lung cancer (72.3%, n = 81). AEs were reported in 566 cycles (94%) out of a total 
      of 602 chemotherapy cycles. Diarrhea was the most common AE (180 cycles, 29.9%) 
      developing after a mean (standard deviation) duration of 3.6 (2.5) days and 
      lasting for 4 (3.3) days. Vomiting (138 cycles, 22.9%) and constipation (121 
      cycles, 20.1%) were other common AEs. Grade 3/4 AEs occurred in 6.9% (39/566) 
      cycles. Need-based SCMs were required in 479 of the 566 cycles (84.6%). 
      Proportion of patients with Grade 3/4 AEs and hospitalization was highest for 
      mucositis (16.1% Grade 3/4 and 9.7% hospitalized); followed by vomiting (10.1% 
      Grade 3/4 and 8.7% hospitalized). Anemia was seen in 441 of 602 chemotherapy 
      cycles (73.3%). Frequency and severity of anemia continued to increase with each 
      chemotherapy cycle. CONCLUSION: LC chemotherapy has a high prevalence of AEs. 
      However, the majority are low grade recovering with need-based SCMs, without any 
      need for hospitalization.
FAU - Muthu, Valliappan
AU  - Muthu V
AD  - Department of Pulmonary Medicine, Postgraduate Institute of Medical Education and 
      Research, Chandigarh, India.
FAU - Mylliemngap, Badari
AU  - Mylliemngap B
AD  - Department of Internal Medicine, Postgraduate Institute of Medical Education and 
      Research, Chandigarh, India.
FAU - Prasad, Kuruswamy Thurai
AU  - Prasad KT
AD  - Department of Pulmonary Medicine, Postgraduate Institute of Medical Education and 
      Research, Chandigarh, India.
FAU - Behera, Digambar
AU  - Behera D
AD  - Department of Pulmonary Medicine, Postgraduate Institute of Medical Education and 
      Research, Chandigarh, India.
FAU - Singh, Navneet
AU  - Singh N
AD  - Department of Pulmonary Medicine, Postgraduate Institute of Medical Education and 
      Research, Chandigarh, India.
LA  - eng
PT  - Journal Article
PL  - India
TA  - Lung India
JT  - Lung India : official organ of Indian Chest Society
JID - 8405380
PMC - PMC6330793
OTO - NOTNLM
OT  - Adenocarcinoma
OT  - anemia
OT  - chemoradiotherapy
OT  - malignancy
OT  - toxicity
COIS- None
EDAT- 2019/01/04 06:00
MHDA- 2019/01/04 06:01
PMCR- 2019/01/01
CRDT- 2019/01/04 06:00
PHST- 2019/01/04 06:00 [entrez]
PHST- 2019/01/04 06:00 [pubmed]
PHST- 2019/01/04 06:01 [medline]
PHST- 2019/01/01 00:00 [pmc-release]
AID - LungIndia_2019_36_1_32_249167 [pii]
AID - LI-36-32 [pii]
AID - 10.4103/lungindia.lungindia_321_17 [doi]
PST - ppublish
SO  - Lung India. 2019 Jan-Feb;36(1):32-37. doi: 10.4103/lungindia.lungindia_321_17.